Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 4/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 2/20 | 0.47 |
| ▸ | PLAT | P00750 | 2/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145553 | 0.88 | MAPT (0.49) | NPC1RAB9AKMT2APLAUMEN1 | |
| SCHEMBL2145538 | 0.87 | POLB (0.47) | NPC1RAB9AKMT2APTGDR2MEN1 | |
| SCHEMBL2145528 | 0.84 | NPC1 (0.49) | NPC1RAB9AKMT2APTGDR2MEN1 | |
| SCHEMBL2145693 | 0.83 | SMN1; SMN2 (0.52) | NPC1RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL2145324 | 0.83 | ALDH1A1 (0.55) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2145206 | 0.83 | RAB9A (0.49) | NPC1RAB9AKMT2APTGDR2MEN1 | |
| SCHEMBL2145122 | 0.82 | L3MBTL1 (0.53) | NPC1RAB9AKMT2APTGDR2MEN1 | |
| SCHEMBL2145325 | 0.82 | NR1H4 (0.53) | NPC1RAB9AKMT2ANR1H4DEGS1 | |
| SCHEMBL2145641 | 0.80 | RAB9A (0.46) | NPC1RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL2145625 | 0.80 | HDAC1 (0.44) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040702-B1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | claimed |
| EP-2040702-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Merck Patent GmbH (DE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008006432-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2008-01-17 | — | — | WO | claimed |
| US-8329738-B2 | Use of AMPK-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-12-11 | — | — | US | disclosed |
| EP-2040702-B1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| EP-2040702-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Merck Patent GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006432-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PRKAG1, PRKAB1, PRKAG2 | NPC1 1430/4885RAB9A 2518/4885KMT2A 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.